A Phase 3 interventional study of Palivizumab in Respiratory Syncytial Virus (RSV), sponsored by AbbVie. Completed. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2018-03-13.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3b, prospective, multicenter, open-label, non-controlled study to assess the safety and effectiveness of immunoprophylaxis with the intramuscular (IM) administration of the liquid formulation of palivizumab for the prevention of RSV hospitalizations in infants at high risk (infants born at less than or equal to 35 weeks gestational age and less than or equal to 6 months of age at enrollment; or infants less than or equal to 24 months of age with a diagnosis of chronic lung disease [CLD] of prematurity requiring on-going medical treatment within the previous 6 months or infants less than or equal to 24 months of age with hemodynamically significant congenital heart disease [CHD]).
Participants will receive palivizumab solution for injection at 15 mg/kg by IM injection every 30 days for a minimum of 3 and a maximum of 5 injections given during anticipated periods of RSV risk in the community; the number of doses will depend on the time of enrollment during the RSV season.
362 studies on the registry are indexed under Bronchopulmonary Dysplasia; 84 are open to participants now.
This study's enrollment of 50 is below the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.
Browse Bronchopulmonary Dysplasia studies →AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Infants at high risk of severe RSV infection defined as fulfilling at least one of the following:
Exclusion Criteria (main exclusion criteria):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single IM injection every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a participant was enrolled.
Drug: Palivizumab
Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.
Also known as: Synagis
Percentage of Participants With RSV Hospitalization
An RSV hospitalization is defined as either 1) a respiratory/cardiac hospitalization with a positive RSV test, 2) new onset of respiratory/cardiac symptoms in an already hospitalized child, with an objective measure of worsening respiratory/cardiac status and a positive RSV test, or 3) deaths, which can be demonstrated as caused by RSV (by autopsy or clinical history and virologic evidence).
Time frame: Approximately 6 months
Total Number of RSV-Hospitalization Days
Time frame: Approximately 6 months
Percentage of Participants Who Received Supplemental Oxygen While Hospitalized
Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.
Time frame: Approximately 6 months
Total RSV-hospitalization Days With Increased Supplemental Oxygen Requirement
Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.
Time frame: Approximately 6 months
Number of Intensive Care Unit (ICU) Admissions During RSV-hospitalization
Time frame: Approximately 6 months
Total Days of RSV-ICU Stay
Time frame: Approximately 6 months
Percentage of Participants Who Received Mechanical Ventilation
Time frame: Approximately 6 months
Total Days of Mechanical Ventilation During RSV-hospitalization
Time frame: Approximately 6 months
| Milestone | Children at High Risk of Severe RSV Infection |
|---|---|
| Started | 50 |
| Completed | 49 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
An RSV hospitalization is defined as either 1) a respiratory/cardiac hospitalization with a positive RSV test, 2) new onset of respiratory/cardiac symptoms in an already hospitalized child, with an objective measure of worsening respiratory/cardiac status and a positive RSV test, or 3) deaths, which can be demonstrated as caused by RSV (by autopsy or clinical history and virologic evidence).
| percentage of participants | Children at High Risk of Severe RSV Infection |
|---|---|
| Percentage of Participants With RSV Hospitalization | 0.0 (0.0 to 7.1) |
No measurements were reported for this outcome.
Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.
No measurements were reported for this outcome.
Increased supplemental oxygen is defined as a new requirement or an increase in supplemental oxygen from prior to the onset of cardiac/respiratory symptoms.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over From first dose of study treatment through the last prophylaxis visit (up to Day 120 [±5 days]) + 30 days (+5 days) and 100 days (+5 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PALIVIZUMAB TEAE Within 30 Days | 0/50 (0%) | 6/50 (12%) | 0/50 (0%) |
| PALIVIZUMAB TEAE Within 100 Days | 0/50 (0%) | 6/50 (12%) | 0/50 (0%) |
| Event | PALIVIZUMAB TEAE Within 30 Days | PALIVIZUMAB TEAE Within 100 Days |
|---|---|---|
| Tachycardia paroxysmalCardiac disorders | 1/50 | 1/50 |
| BronchitisInfections and infestations | 1/50 | 1/50 |
| Bronchitis viralInfections and infestations | 1/50 | 1/50 |
| NasopharyngitisInfections and infestations | 1/50 | 1/50 |
| PneumoniaInfections and infestations | 1/50 | 1/50 |
| Respiratory tract infection viralInfections and infestations | 1/50 | 1/50 |
| HaemangiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/50 | 1/50 |
| Age, Continuous(months) | Children at High Risk of Severe RSV Infection |
|---|---|
| Mean | 6.22 ± 4.428 |
| Sex: Female, Male(Participants) | Children at High Risk of Severe RSV Infection |
|---|---|
| Female | 24 |
| Male | 26 |
| Ethnicity (NIH/OMB)(Participants) | Children at High Risk of Severe RSV Infection |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 50 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Children at High Risk of Severe RSV Infection |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 50 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Jul 2017, 8 months.
Results were first posted in Mar 2018, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palivizumab